Table 1.

Clinical characteristics and immune phenotypes^a

Clinical Characteristics	IF (n=13)	IS (n=12)	HC (n=9)
% male	85	50	89
Age (years)
At study enrollment	54 (34–64)	49 (32–60)	46 (30–61)
At ART initiation	44 (19–49)	35 (25–53)	-
CD4 T cells/mL	294 (141–378)	745 (566–1919)	-
Nadir CD4 (cells/mL)	56 (0–180)	60 (4–354)	-
Years with undetectable plasma HIV RNA	7 (2–17)	6 (2–15)	-
Co-infection (seropositive; n(%))
CMV	12 (92)	9 (82)	-
Hepatitis B	1 (8)	0 (0)	-
Hepatitis C	2 (17)	0 (0)	-
Immune phenotypesb
% CD4+/CD3+c,d	34 (9–42)	46 (26–66)	74 (42–79)
% naïvec,e	24 (4–48)	35 (2–56)	56 (30–71)
% CM	46 (29–82)	46 (30–79)	37 (22–59)
% EMc,e	9 (6–62)	11 (7–21)	7 (3–15)
% TM	2 (0.1–10)	1.4 (0.1–8)	0.4 (0.2–0.9)
% Ki-67+ in total CD4c,d	4 (2–6)f	2 (1–4)
% Ki-67 in naïve CD4c	0.4 (0.2–2)	0.2 (0–1)
% Ki-67 in CM CD4c,d	5 (2–8)	2 (1–7)
% Ki-67 in EM CD4c	7 (3–16)	4 (3–7)
% CD38+ in memoryd	29 (19–66)	16 (5–38)	21 (11–32)

^aMedian (range)

^bcentral memory, CM, CD45RA-CD27+; effector memory, EM, CD45RA-CD27−; terminal memory, TM, CD45RA+CD27−; naïve (CD45RA+CD27+) Statistically significant comparisons (p<0.05):

^cIF vs HC;

^dIF vs IS;

^eIS vs HC

^fn=12